How Blinatumomab Is Utilized in ALL Management

Jonathan Webster, MD, and Nikesh Shah, MD, examine the expanding role of blinatumomab (Blincyto) across multiple stages of ALL therapy, including its use in consolidation, minimal residual disease (MRD)–directed treatment, and relapse settings. They discuss the clinical benefits of this bispecific T-cell engager, such as its ability to achieve deep molecular responses and reduce relapse risk. Webster and Shah also address practical considerations, including administration logistics and toxicity monitoring.